Shenfushu granules attenuate diabetic kidney disease by inhibiting PIK3R1/protein kinase B/heparanase-mediated endothelial-mesenchymal transition

Figure 3 Shenfushu granules inhibits endothelial-mesenchymal transition in glomeruli. A: Representative images of immunohistochemistry staining for cluster of differentiation (CD) 31 (630 × magnification, scale bar: 25 μm); B: Representative images of immunohistochemistry staining for α-smooth muscle actin (α-SMA) (630 × magnification, scale bar: 25 μm); C: Western blot analysis of CD31 and α-SMA expression. β-actin was used as the loading control; D: Densitometric analyses of CD31; E: Densitometric analyses of α-SMA. The data are presented as the mean ± SE (n ≥ 3). ^aP < 0.05. ^bP < 0.01. ^cP < 0.001. ¹P vs control group. ²P vs model group. IF: Immunofluorescence; CD31: Cluster of differentiation 31; α-SMA: α-smooth muscle actin; DAPI: 4’,6-diamidino-2-phenylindole; SFSGs: Shenfushu granules; L: Low; M: Middle; H: High.